Literature DB >> 29299482

Have the annual trends of total hip arthroplasty in rheumatoid arthritis patients decreased?

Kemjika O Onuoha1, Max Solow2, Jared M Newman1, Nipun Sodhi3, Robert Pivec1, Anton Khlopas3, Assem A Sultan3, Morad Chughtai3, Neil V Shah1, Jaiben George3, Michael A Mont3.   

Abstract

BACKGROUND: Rheumatoid arthritis (RA) is characterized by chronic systemic and synovial inflammation, resulting in damage to both cartilage and bone. Medical treatment, which has increasingly relied upon disease modifying anti-rheumatic drugs (DMARDs), may fail to slow disease progression and limit joint damage, ultimately warranting surgical intervention. Up to 25% of RA patients will require lower extremity total joint arthroplasty. Though total hip arthroplasty (THA) is known to improve quality of life and functional measures, clarification is still required with respect to the impact of increased DMARD use on annual rates of THA. Thus, the purpose of this study was to evaluate: (I) the annual trends of THAs due to RA in the United States population; (II) the annual trends in the proportion of THAs due to RA in the United States.
METHODS: This study utilized the Nationwide Inpatient Sample (NIS) to identify all patients who underwent THA between 2002 and 2013 (n=3,135,904). Then, THA patients who had a diagnosis of RA, which was defined by the International Classification of Disease 9th revision diagnosis code 714.0, were identified. The incidence of THAs with a diagnosis of RA in the United States was calculated using the United States population as the denominator. Regression models were used to analyze the annual trends of RA in patients who underwent THA.
RESULTS: Review of the database identified 90,487 patients who had a diagnosis of RA and underwent THA from 2002 to 2013. The annual prevalence of RA in those who underwent THA slightly decreased over the specified time period, with 28.7 per 1,000 THAs in 2002 and 28.6 per 1,000 THAs in 2013; however, this change was not statistically significant (R2=0.158, P=0.200).
CONCLUSIONS: The annual rates of THA among RA patients did not show any significant change between 2002 and 2013. DMARD use has decreased both disease progression and joint destruction, and DMARDs are now often utilized as primary treatment. The increase in population of the country during the study period may have overestimated THA trends. Moreover, patients may be more likely to opt for surgical management, given the advances in operative techniques as well as peri- and post-operative course.

Entities:  

Keywords:  Rheumatoid arthritis (RA); annual trends; total hip arthroplasty (THA)

Year:  2017        PMID: 29299482      PMCID: PMC5750265          DOI: 10.21037/atm.2017.11.15

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


  33 in total

1.  Declining use of orthopedic surgery in patients with rheumatoid arthritis? Results of a long-term, population-based assessment.

Authors:  Eleonora da Silva; Michele F Doran; Cynthia S Crowson; W Michael O'Fallon; Eric L Matteson
Journal:  Arthritis Rheum       Date:  2003-04-15

Review 2.  Rheumatoid arthritis disease severity indices in administrative databases: a systematic review.

Authors:  Evelyne Vinet; Bindee Kuriya; Jessica Widdifield; Sasha Bernatsky
Journal:  J Rheumatol       Date:  2011-09-15       Impact factor: 4.666

3.  Cementless femoral components in bicondylar hybrid knee arthroplasty in patients with rheumatoid arthritis: A 10-year survivorship analysis.

Authors:  Thilo Hotfiel; Hans-Dieter Carl; Teresa Eibenberger; Kolja Gelse; Julian Weiß; Andreas Jendrissek; Bernd Swoboda
Journal:  J Orthop Surg (Hong Kong)       Date:  2017 May-Aug       Impact factor: 1.118

4.  A comparison of quality of life before and after arthroplasty in patients who had arthrosis of the hip joint.

Authors:  I Wiklund; B Romanus
Journal:  J Bone Joint Surg Am       Date:  1991-06       Impact factor: 5.284

5.  The effect of a new multimodal perioperative anesthetic regimen on postoperative pain, side effects, rehabilitation, and length of hospital stay after total joint arthroplasty.

Authors:  Christopher L Peters; Brayton Shirley; Jill Erickson
Journal:  J Arthroplasty       Date:  2006-09       Impact factor: 4.757

6.  Health related quality of life outcomes after total hip and knee arthroplasties in a community based population.

Authors:  C A Jones; D C Voaklander; D W Johnston; M E Suarez-Almazor
Journal:  J Rheumatol       Date:  2000-07       Impact factor: 4.666

7.  Is administratively coded comorbidity and complication data in total joint arthroplasty valid?

Authors:  Kevin J Bozic; Ravi K Bashyal; Shawn G Anthony; Vanessa Chiu; Brandon Shulman; Harry E Rubash
Journal:  Clin Orthop Relat Res       Date:  2013-01       Impact factor: 4.176

Review 8.  Treatment of rheumatoid arthritis.

Authors:  Angelo Gaffo; Kenneth G Saag; Jeffrey R Curtis
Journal:  Am J Health Syst Pharm       Date:  2006-12-15       Impact factor: 2.637

9.  Rheumatoid arthritis patients undergoing total hip and knee arthroplasty have better in-hospital outcomes compared with non-rheumatoid arthritis patients.

Authors:  Hiroyuki Yoshihara; Daisuke Yoneoka; Adam Margalit; Joseph D Zuckerman
Journal:  Clin Exp Rheumatol       Date:  2016-02-09       Impact factor: 4.473

Review 10.  Biologic monotherapy in the treatment of rheumatoid arthritis.

Authors:  Jacqueline Detert; Pascal Klaus
Journal:  Biologics       Date:  2015-05-14
View more
  3 in total

Review 1.  [Change in rheumatic hip surgery].

Authors:  J Holinka
Journal:  Z Rheumatol       Date:  2018-12       Impact factor: 1.372

2.  Factors Associated With Increasing Length of Stay for Rheumatoid Arthritis Patients Undergoing Total Hip Arthroplasty and Total Knee Arthroplasty.

Authors:  Kyle W Morse; Nicole K Heinz; Jeremy M Abolade; Joshua Wright-Chisem; Linda Alice Russell; Meng Zhang; Serene Mirza; Diyu Pearce-Fisher; Dana E Orange; Mark P Figgie; Peter K Sculco; Susan M Goodman
Journal:  HSS J       Date:  2022-02-22

3.  Cost-Effectiveness of Repository Corticotropin Injection versus Standard of Care for the Treatment of Active Rheumatoid Arthritis.

Authors:  Jas Bindra; Ishveen Chopra; John Niewoehner; Mary Panaccio; George J Wan
Journal:  Clinicoecon Outcomes Res       Date:  2021-05-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.